Cisplatin is the most important and classic first‐line synchronous chemotherapeutic agent for the treatment of nasopharyngeal carcinoma; and EBV‐LMP1 regulates cellular cisplatin resistance through multiple signaling pathways (Tang et al, 2018). The gene discussed is PDLIM7; the disease is nasopharyngeal carcinoma.